{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:51:19Z","timestamp":1780145479626,"version":"3.54.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["21-2060\/SRGP\/R&D\/HEC\/2018"],"award-info":[{"award-number":["21-2060\/SRGP\/R&D\/HEC\/2018"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00705-020-04901-2","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T18:59:40Z","timestamp":1612292380000},"page":"1047-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interferon-\u03bb rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population"],"prefix":"10.1007","volume":"166","author":[{"given":"Bisma","family":"Rauff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafiq Ahmad","family":"Chudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghias Un Nabi","family":"Tayyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-6382","authenticated-orcid":false,"given":"Rumeza","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"issue":"5 Suppl 1","key":"4901_CR1","first-page":"S35","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology (Baltimore, MD) 36(5 Suppl 1):S35-46","journal-title":"Hepatology (Baltimore, MD)"},{"key":"4901_CR2","unstructured":"(WHO) WHO. Hepatitis C. Fact sheet. 2017, updated July, 2019 [updated 2020\/05\/23\/11:57:29; cited 2020]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"issue":"4","key":"4901_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1478-3231.2011.02449.x","volume":"31","author":"M Romero-Gomez","year":"2011","unstructured":"Romero-Gomez M, Eslam M, Ruiz A, Maraver M (2011) Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 31(4):443\u2013460","journal-title":"Liver Int"},{"issue":"4","key":"4901_CR4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0035-1567830","volume":"35","author":"M Eslam","year":"2015","unstructured":"Eslam M, George J (2015) Genome-wide association studies and hepatitis C: harvesting the benefits of the genomic revolution. Semin Liver Dis 35(4):402\u2013420","journal-title":"Semin Liver Dis"},{"issue":"7","key":"4901_CR5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","volume":"40","author":"M Eslam","year":"2019","unstructured":"Eslam M, George J (2019) Genetic insights for drug development in NAFLD. Trends Pharmacol Sci 40(7):506\u2013516","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4901_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2020","unstructured":"Eslam M, George J (2020) Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol 17(1):40\u201352","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"4901_CR7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","volume":"36","author":"A Bayoumi","year":"2020","unstructured":"Bayoumi A, Gr\u00f8nb\u00e6k H, George J, Eslam M (2020) The epigenetic drug discovery landscape for metabolic-associated fatty liver disease. Trends Genet 36(6):429\u2013441","journal-title":"Trends Genet"},{"issue":"10","key":"4901_CR8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/jir.2018.0175","volume":"39","author":"M Eslam","year":"2019","unstructured":"Eslam M, Ahlenstiel G, George J (2019) Interferon lambda and liver fibrosis. J Interferon Cytokine Res 39(10):627\u2013635","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"4901_CR9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2012.05.016","volume":"57","author":"E Estrabaud","year":"2012","unstructured":"Estrabaud E, Vidaud M, Marcellin P, Asselah T (2012) Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 57(5):1110\u20131125","journal-title":"J Hepatol"},{"key":"4901_CR10","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1038\/ncomms7422","volume":"6","author":"M Eslam","year":"2015","unstructured":"Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ et al (2015) Interferon-\u03bb rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 6:6422","journal-title":"Nat Commun"},{"issue":"2","key":"4901_CR11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2015.11.008","volume":"64","author":"M Eslam","year":"2016","unstructured":"Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A et al (2016) FibroGENE: a gene-based model for staging liver fibrosis. J Hepatol 64(2):390\u2013398","journal-title":"J Hepatol"},{"issue":"2","key":"4901_CR12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.28322","volume":"63","author":"MA Burza","year":"2016","unstructured":"Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM et al (2016) DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology (Baltimore, MD) 63(2):418\u2013427","journal-title":"Hepatology (Baltimore, MD)"},{"key":"4901_CR13","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1038\/ncomms12757","volume":"7","author":"K Thabet","year":"2016","unstructured":"Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL et al (2016) MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun 7:12757","journal-title":"Nat Commun"},{"issue":"1","key":"4901_CR14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-018-35736-2","volume":"9","author":"RE Sharkawy","year":"2019","unstructured":"Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M et al (2019) A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-\u03b21 dependent mechanisms. Sci Rep 9(1):1439","journal-title":"Sci Rep"},{"issue":"7262","key":"4901_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399\u2013401","journal-title":"Nature"},{"issue":"10","key":"4901_CR16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41(10):1100\u20131104","journal-title":"Nat Genet"},{"issue":"10","key":"4901_CR17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al (2009) Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105\u20131109","journal-title":"Nat Genet"},{"issue":"2","key":"4901_CR18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/hep.24678","volume":"55","author":"P-Y Bochud","year":"2012","unstructured":"Bochud P-Y, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B et al (2012) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (Baltimore, MD) 55(2):384\u2013394","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"4901_CR19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/ng.3836","volume":"49","author":"M Eslam","year":"2017","unstructured":"Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K et al (2017) IFN-\u03bb3, not IFN-\u03bb4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 49(5):795\u2013800","journal-title":"Nat Genet"},{"issue":"12","key":"4901_CR20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/14728222.2016.1241242","volume":"20","author":"M Eslam","year":"2016","unstructured":"Eslam M, George J (2016) Targeting IFN-\u03bb: therapeutic implications. Expert Opin Ther Tar 20(12):1425\u20131432","journal-title":"Expert Opin Ther Tar"},{"issue":"41","key":"4901_CR21","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.3748\/wjg.v19.i41.7055","volume":"19","author":"M Eslam","year":"2013","unstructured":"Eslam M, Booth DR, George J, Ahlenstiel G (2013) Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World J Gastroenterol 19(41):7055\u20137061","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4901_CR22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/infdis\/jir113","volume":"203","author":"P Barreiro","year":"2011","unstructured":"Barreiro P, Pineda JA, Rall\u00f3n N, Naggie S, Mart\u00edn-Carbonero L, Neukam K et al (2011) Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 203(11):1629\u20131636","journal-title":"J Infect Dis"},{"issue":"2","key":"4901_CR23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jinf.2012.10.025","volume":"66","author":"M Guzm\u00e1n-Fulgencio","year":"2013","unstructured":"Guzm\u00e1n-Fulgencio M, Berenguer J, Garc\u00eda-\u00c1lvarez M, Fern\u00e1ndez-Rodr\u00edguez A, Jim\u00e9nez-Sousa MA, \u00c1lvarez E et al (2013) IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. J Infect 66(2):170\u2013178","journal-title":"J Infect"},{"issue":"1","key":"4901_CR24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiw088","volume":"214","author":"N Moqueet","year":"2016","unstructured":"Moqueet N, Cooper C, Gill J, Hull M, Platt RW, Klein MB et al (2016) Responder interferon \u03bb genotypes are associated with higher risk of liver fibrosis in HIV-hepatitis C virus coinfection. J Infect Dis 214(1):80\u201386","journal-title":"J Infect Dis"},{"issue":"6","key":"4901_CR25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.29395","volume":"66","author":"S Petta","year":"2017","unstructured":"Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Camm\u00e0 C et al (2017) Interferon lambda 4 rs368234815 TT>\u03b4G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 66(6):1885\u20131893","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"4901_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MEG.0000000000000813","volume":"29","author":"A Uygun","year":"2017","unstructured":"Uygun A, Ozturk K, Demirci H, Oztuna A, Eren F, Kozan S et al (2017) The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. Eur J Gastroenterol Hepatol 29(4):441\u2013447","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"4901_CR27","doi-asserted-by":"crossref","first-page":"e0166998","DOI":"10.1371\/journal.pone.0166998","volume":"11","author":"T Aiken","year":"2016","unstructured":"Aiken T, Garber A, Thomas D, Hamon N, Lopez R, Konjeti R et al (2016) Donor IFNL4 genotype is associated with early post-transplant fibrosis in recipients with hepatitis C. PLoS One 11(11):e0166998","journal-title":"PLoS One"},{"issue":"1","key":"4901_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"M Metwally","year":"2019","unstructured":"Metwally M, Thabet K, Bayoumi A, Nikpour M, Stevens W, Sahhar J et al (2019) IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Sci Rep UK 9(1):1\u20135","journal-title":"Sci Rep UK"},{"key":"4901_CR29","unstructured":"(WHO) WHO. Fighting hepatitis in Pakistan 2017 [updated 2020\/05\/26\/10:25:58; cited 2020]. Available from: https:\/\/www.who.int\/news-room\/pakistan-tackles-high-rates-of-hepatitis-from-many-angles"},{"issue":"10123","key":"4901_CR30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(18)30462-8","volume":"391","author":"A Moin","year":"2018","unstructured":"Moin A, Fatima H, Qadir TF (2018) Tackling hepatitis C\u2014Pakistan\u2019s road to success. Lancet 391(10123):834\u2013835","journal-title":"Lancet"},{"issue":"4","key":"4901_CR31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrg2554","volume":"10","author":"KA Frazer","year":"2009","unstructured":"Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10(4):241\u2013251","journal-title":"Nat Rev Genet"},{"issue":"12","key":"4901_CR32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph J-M, Yon S, Fournier C, Mal F et al (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705\u20131713","journal-title":"Ultrasound Med Biol"},{"issue":"2","key":"4901_CR33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343\u2013350","journal-title":"Gastroenterology"},{"issue":"1","key":"4901_CR34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","volume":"41","author":"M Ziol","year":"2005","unstructured":"Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F et al (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41(1):48\u201354","journal-title":"Hepatology"},{"issue":"7","key":"4901_CR35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.2006.111302","volume":"56","author":"M Fraquelli","year":"2007","unstructured":"Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G et al (2007) Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56(7):968\u2013973","journal-title":"Gut"},{"issue":"5","key":"4901_CR36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48(5):835\u2013847","journal-title":"J Hepatol"},{"issue":"1","key":"4901_CR37","doi-asserted-by":"crossref","first-page":"e000316","DOI":"10.1136\/bmjgast-2019-000316","volume":"6","author":"A Hussain","year":"2019","unstructured":"Hussain A, Gul MA, Khalid MU (2019) Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). BMJ Open Gastroenterol 6(1):e000316","journal-title":"BMJ Open Gastroenterol"},{"issue":"15","key":"4901_CR38","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","volume":"22","author":"X Sol\u00e9","year":"2006","unstructured":"Sol\u00e9 X, Guin\u00f3 E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928\u20131929","journal-title":"Bioinformatics"},{"issue":"2","key":"4901_CR39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/bib\/3.2.146","volume":"3","author":"CM Lewis","year":"2002","unstructured":"Lewis CM (2002) Genetic association studies: design, analysis and interpretation. Brief Bioinform 3(2):146\u2013153","journal-title":"Brief Bioinform"},{"issue":"3","key":"4901_CR40","doi-asserted-by":"crossref","first-page":"e91822","DOI":"10.1371\/journal.pone.0091822","volume":"9","author":"M Sato","year":"2014","unstructured":"Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H et al (2014) Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS ONE 9(3):e91822","journal-title":"PLoS ONE"},{"key":"4901_CR41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.meegid.2017.05.026","volume":"53","author":"L Boglione","year":"2017","unstructured":"Boglione L, Cusato J, Cariti G, Di Perri G, D\u2019Avolio A (2017) Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. J Mol Epidemiol Evol Genet Infect Dis 53:195\u2013198","journal-title":"J Mol Epidemiol Evol Genet Infect Dis"},{"issue":"1","key":"4901_CR42","first-page":"28","volume":"8","author":"H Fereidooni","year":"2017","unstructured":"Fereidooni H, Azarpira N, Yaghobi R, Vahdati A, Malek-Hoseini SA (2017) Interleukin-28B rs12979860 C\/T polymorphism and acute cellular rejection after liver transplantation. Int J Organ Transplant Med 8(1):28\u201333","journal-title":"Int J Organ Transplant Med"},{"issue":"5","key":"4901_CR43","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.26506","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (Baltimore, MD) 58(5):1548\u20131557","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"4901_CR44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2011.050351","volume":"97","author":"V Di Marco","year":"2012","unstructured":"Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A et al (2012) IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 97(5):679\u2013686","journal-title":"Haematologica"},{"issue":"4","key":"4901_CR45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.24503","volume":"54","author":"F Marabita","year":"2011","unstructured":"Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R et al (2011) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (Baltimore, MD) 54(4):1127\u20131134","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"4901_CR46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10875-011-9547-1","volume":"31","author":"E Falleti","year":"2011","unstructured":"Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S et al (2011) Role of Interleukin 28B rs12979860 C\/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 31(5):891\u2013899","journal-title":"J Clin Immunol"},{"issue":"3","key":"4901_CR47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","volume":"53","author":"H Abe","year":"2010","unstructured":"Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D et al (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53(3):439\u2013443","journal-title":"J Hepatol"},{"issue":"7","key":"4901_CR48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4067\/s0034-98872018000700823","volume":"146","author":"J Brahm","year":"2018","unstructured":"Brahm J, Urz\u00faa A, Poniachik J, C\u00e1ceres DD, Carre\u00f1o L, Venegas M (2018) Interferon Lambda 4 RS12979860 C>T polymorphism is not associated with liver fibrosis in patients with hepatitis C. Rev Med Chil 146(7):823\u2013829","journal-title":"Rev Med Chil"},{"issue":"3","key":"4901_CR49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clinre.2012.09.012","volume":"37","author":"NM Rizk","year":"2013","unstructured":"Rizk NM, Derbala MF (2013) Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. Clin Res Hepatol Gastroenterol 37(3):262\u2013268","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"4901_CR50","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1080\/00365521.2019.1643403","volume":"54","author":"R Shridhar Gulati","year":"2019","unstructured":"Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H et al (2019) The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scand J Gastroenterol 54(9):1172\u20131175","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"4901_CR51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5604\/01.3001.0012.0918","volume":"17","author":"AM Attallah","year":"2018","unstructured":"Attallah AM, Omran D, Omran MM, Abdelrazek MA, Zayed R, Essawey RE et al (2018) Extracellular matrix proteins substantiate IL-28B T allele effect on histological outcome of chronic hepatitis C. Ann Hepatol 17(4):569\u2013576","journal-title":"Ann Hepatol"},{"issue":"5","key":"4901_CR52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jmv.23259","volume":"84","author":"C Fabris","year":"2012","unstructured":"Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Colletta C et al (2012) The interleukin 28B rs12979860 C\/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Med Virol. 84(5):747\u2013755","journal-title":"J Med Virol."},{"issue":"11","key":"4901_CR53","doi-asserted-by":"crossref","first-page":"e80172","DOI":"10.1371\/journal.pone.0080172","volume":"8","author":"M Ydreborg","year":"2013","unstructured":"Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A et al (2013) Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS ONE 8(11):e80172","journal-title":"PLoS ONE"},{"issue":"1","key":"4901_CR54","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1186\/s40064-016-3663-6","volume":"5","author":"A Mangia","year":"2016","unstructured":"Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J et al (2016) IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus 5(1):1990. https:\/\/doi.org\/10.1186\/s40064-016-3663-6","journal-title":"Springerplus"},{"issue":"5","key":"4901_CR55","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/hep.29659","volume":"67","author":"H Park","year":"2018","unstructured":"Park H, O\u2019Brien TR, Rehermann B (2018) The role of genetics in hepatic fibrosis among hepatitis C virus patients. Hepatology (Baltimore, MD) 67(5):2043\u20132045","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"4901_CR56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/jvh.12127","volume":"21","author":"B Baran","year":"2014","unstructured":"Baran B, Gulluoglu M, Soyer OM, Ormeci AC, Gokturk S, Evirgen S et al (2014) Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat 21(2):111\u2013120","journal-title":"J Viral Hepat"},{"issue":"1","key":"4901_CR57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7883\/yoken.JJID.2017.089","volume":"71","author":"HI Shousha","year":"2018","unstructured":"Shousha HI, Awad AH, Omran DA, Elnegouly MM, Mabrouk M (2018) Data mining and machine learning algorithms using IL28B genotype and biochemical markers best predicted advanced liver fibrosis in chronic hepatitis C. Jpn J Infect Dis. 71(1):51\u201357","journal-title":"Jpn J Infect Dis."},{"issue":"3","key":"4901_CR58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/gene.2017.12","volume":"18","author":"M Asnavandi","year":"2017","unstructured":"Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A et al (2017) EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 18(3):144\u2013151","journal-title":"Genes Immun"},{"key":"4901_CR59","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.meegid.2017.07.023","volume":"54","author":"F Sakhaee","year":"2017","unstructured":"Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S et al (2017) The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol 54:330\u2013337","journal-title":"Infect Genet Evol"},{"issue":"5","key":"4901_CR60","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1002\/jcb.28096","volume":"120","author":"N El-Khazragy","year":"2019","unstructured":"El-Khazragy N, Sayed NE, Salem AM, Hassan NS, Abdelmoeaz AT, Maher AM et al (2019) IL-28\u03b2 gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients. J Cell Biochem 120(5):8154\u20138159","journal-title":"J Cell Biochem"},{"issue":"6","key":"4901_CR61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00439-020-02136-4","volume":"139","author":"P Nahon","year":"2020","unstructured":"Nahon P, Cobat A (2020) Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 139(6):855\u2013863","journal-title":"Hum Genet"},{"issue":"4","key":"4901_CR62","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00705-018-3711-3","volume":"163","author":"H Naeemi","year":"2018","unstructured":"Naeemi H, Aslam R, Raza SM, Shahzad MA, Naz S, Manzoor S et al (2018) Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol 163(4):997\u20131008","journal-title":"Arch Virol"},{"issue":"2","key":"4901_CR63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00430-017-0497-y","volume":"206","author":"A Alborzi","year":"2017","unstructured":"Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S (2017) Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 206(2):165\u2013174","journal-title":"Med Microbiol Immunol"},{"key":"4901_CR64","doi-asserted-by":"crossref","unstructured":"de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA et al (2018) Hepatitis C virus-infected responders and relapsers to treatment show similar genetic profiles of IL28B and IL10 single nucleotide polymorphisms. Biomed Res Int","DOI":"10.1155\/2018\/2931486"},{"issue":"3","key":"4901_CR65","doi-asserted-by":"crossref","first-page":"o110","DOI":"10.1093\/ofid\/ofu110","volume":"1","author":"TR O'Brien","year":"2014","unstructured":"O\u2019Brien TR, Lang Kuhs KA, Pfeiffer RM (2014) Subgroup differences in response to 8 weeks of ledipasvir\/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 1(3):o110","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"4901_CR66","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1053\/j.gastro.2017.06.069","volume":"153","author":"TR O\u2019Brien","year":"2017","unstructured":"O\u2019Brien TR, Kottilil S, Pfeiffer RM (2017) IFNL4 genotype is associated with virologic relapse after 8-week treatment with sofosbuvir, velpatasvir and voxilaprevir. Gastroenterology 153(6):1694\u20131695","journal-title":"Gastroenterology"},{"issue":"4","key":"4901_CR67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jmv.25359","volume":"91","author":"AJ Khan","year":"2019","unstructured":"Khan AJ, Saraswat VA, Ranjan P, Parmar D, Negi TS, Mohindra S (2019) Polymorphism in interferon \u03bb3\/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. J Med Virol 91(4):659\u2013667","journal-title":"J Med Virol"},{"issue":"0","key":"4901_CR68","first-page":"1","volume":"0","author":"I El-Garawani","year":"2020","unstructured":"El-Garawani I, El-Nabi SH, Gadallah M, Abdelsameea E (2020) Association between IFN-\u03bb 3 gene polymorphisms and outcome of treatment with direct acting antivirals in chronic HCV-infected Egyptian patients. Immunol Invest. 0(0):1\u201311","journal-title":"Immunol Invest."},{"issue":"0","key":"4901_CR69","first-page":"1","volume":"0","author":"SE Ghanem","year":"2020","unstructured":"Ghanem SE, Elsabaawy M, Shebl N, Abdelsameea E, Othman W, El-Bassal FI et al (2020) Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther 0(0):1\u20138","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"4901_CR70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/vim.2017.0124","volume":"31","author":"H Aziz","year":"2018","unstructured":"Aziz H, Aziz M, Gill ML (2018) Analysis of host and viral-related factors associated to direct acting antiviral response in hepatitis C virus patients. Viral Immunol 31(3):256\u2013263","journal-title":"Viral Immunol"},{"key":"4901_CR71","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320666200505113619","author":"A Elsheredy","year":"2020","unstructured":"Elsheredy A, Almaeen A, Ghazy A, Helaly G, Amer I, Ghazy H et al (2020) Impact of interleukin 28B and ICAM-1 genetic polymorphisms on response to direct antiviral treatment among HCV infected patients. Endocr Metab Immune Disord Drug Targets. https:\/\/doi.org\/10.2174\/1871530320666200505113619 (Online ahead of print)","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"4901_CR72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al (2013) A variant upstream of IFNL3 (IL28B) creating a novel interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164\u2013171","journal-title":"Nat Genet"},{"issue":"8","key":"4901_CR73","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00535-014-1023-2","volume":"50","author":"Y Aoki","year":"2015","unstructured":"Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S et al (2015) Association of serum IFN-\u03bb3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol 50(8):894\u2013902","journal-title":"J Gastroenterol"},{"key":"4901_CR74","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/S0168-8278(15)30905-3","volume":"62","author":"JA Holmes","year":"2015","unstructured":"Holmes JA, Skinner N, Congiu M, Millen R, Bell SJ, Nguyen T et al (2015) P0702: CC IL28B Genotype is associated with high liver necroinflammation and increased expression of TH1 cytokines (CYK) and chemokines (CHK), but also higher TH2 CYK which may drive low ISG expression. J Hepatol 62:S586","journal-title":"J Hepatol"},{"issue":"2","key":"4901_CR75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/gene.2013.66","volume":"15","author":"KS O'Connor","year":"2014","unstructured":"O\u2019Connor KS, Parnell G, Patrick E, Ahlenstiel G, Suppiah V, van der Poorten D et al (2014) Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes Immun 15(2):88\u201394","journal-title":"Genes Immun"},{"issue":"3","key":"4901_CR76","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.26788","volume":"59","author":"M Honda","year":"2014","unstructured":"Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K et al (2014) Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology (Baltimore, MD) 59(3):828\u2013838","journal-title":"Hepatology (Baltimore, MD)"},{"key":"4901_CR77","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3389\/fimmu.2019.02674","volume":"10","author":"SA Read","year":"2019","unstructured":"Read SA, Wijaya R, Ramezani-Moghadam M, Tay E, Schibeci S, Liddle C et al (2019) Macrophage coordination of the interferon lambda immune response. Front Immunol 10:2674","journal-title":"Front Immunol"},{"issue":"3","key":"4901_CR78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0030-1255354","volume":"30","author":"TA Wynn","year":"2010","unstructured":"Wynn TA, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30(3):245\u2013257","journal-title":"Semin Liver Dis"},{"issue":"2","key":"4901_CR79","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.chom.2014.01.007","volume":"15","author":"T Sheahan","year":"2014","unstructured":"Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A et al (2014) Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15(2):190\u2013202","journal-title":"Cell Host Microbe"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-020-04901-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T11:33:21Z","timestamp":1671017601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-020-04901-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4901"],"URL":"https:\/\/doi.org\/10.1007\/s00705-020-04901-2","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}